CORT Shares Plummet 50%: Investor Alert on FDA Response!

Key Risks and Red Flags

Corcept faces a number of risks and red flags that investors should monitor closely, especially in light of the FDA setback:

– Pipeline & Regulatory Risk: The relacorilant CRL underscores the risk of pipeline failures. Relacorilant was the company’s lead pipeline candidate and was positioned as the future growth driver replacing Korlym (www.trefis.com). Its rejection by the FDA raises serious questions about Corcept’s pipeline and strategy (www.trefis.com) (www.trefis.com). With no other late-stage products near approval, Corcept lacks revenue diversification in the near term (www.trefis.com). Any further regulatory hurdles (e.g. for relacorilant’s other indications or new trials required) could significantly delay growth. This event highlights the inherent biotech risk that R&D investments might not pan out despite meeting trial endpoints.

– Single-Product Dependency: Corcept’s revenue is 100% dependent on one product, Korlym (mifepristone for Cushing’s). In Q2 2025, for instance, ***all* $194 million of revenue came from Korlym sales (www.nasdaq.com). This concentration makes the company vulnerable – any issues with Korlym’s sales could severely impact financial performance. While Corcept has grown Korlym revenue by expanding the diagnosed patient pool and increasing physician awareness, competition is emerging. New therapies for Cushing’s syndrome (e.g. osilodrostat and levoketoconazole launched in recent years) provide alternative treatment options that could cap Korlym’s market share. Even though Corcept noted that better disease recognition is driving its sales growth (www.biospace.com), future Korlym growth may slow if these competitors gain traction or if fewer new patients are eligible. Relying on a single drug also exposes Corcept to supply, manufacturing, or pricing risks on that product.

– Competition and Generic Threats: Corcept has taken steps to protect Korlym’s franchise, but competitive threats are on the horizon. The company settled a patent lawsuit with Sun Pharma, allowing a generic Korlym entry by October 2034 (ir.corcept.com) – giving Corcept a period of exclusivity. However, other generics makers (e.g. Teva) have not settled; patent litigation with at least two other companies is ongoing (ir.corcept.com). Teva in particular has pursued aggressive legal action, not just via patent courts but by suing Corcept for alleged anticompetitive practices (pm360online.com). If any generic entrant successfully challenges Corcept’s patents before 2034, Korlym could face early generic competition, leading to a sharp revenue decline. Even without generics, alternative Cushing’s drugs (mentioned above) compete for patients. Corcept’s ability to maintain its Korlym monopoly until relacorilant (or another successor) is approved remains a significant uncertainty.

– Legal & Compliance Red Flags: Serious allegations about Corcept’s business practices have surfaced. In late 2021, Corcept disclosed receiving a DOJ subpoena seeking information on Korlym sales, marketing, and payments to physicians (thecapitolforum.com). A Capitol Forum investigation suggested Corcept may have promoted Korlym’s off-label use and pushed lower diagnostic criteria to broaden its patient base (thecapitolforum.com) (thecapitolforum.com). Such practices, if confirmed, could violate laws and lead to fines or sanctions. Separately, Teva’s 2024 lawsuit accuses Corcept and its specialty pharmacy partner of a “multifaceted scheme” to stifle competition, including exclusive distribution to block generic access and even “paying bribes and kickbacks” to doctors to favor Korlym (pm360online.com). These are serious red flags regarding compliance and ethics. While Corcept’s management has not been found liable of wrongdoing to date, the ongoing DOJ investigation and civil litigation pose reputational and financial risks. A negative outcome (e.g. a large settlement or judgment) could not only hit Corcept with financial penalties but also force changes in how it sells Korlym (potentially hurting sales). Investors should be mindful that governance and conduct issues hang over the company.

– Execution & Cost Risks: Corcept’s operating expenses are rising significantly as it invests in clinical trials and commercial efforts. As noted, SG&A spiked over 50% year-on-year in recent quarters (www.nasdaq.com), and R&D spend remains high with multiple pipeline programs in development. If new product approvals don’t materialize on schedule, the company could face a scenario of escalating costs without offsetting new revenues, crimping margins. The relacorilant CRL may force Corcept to fund additional trials or data generation to satisfy the FDA – an unplanned expense that will weigh on profitability in coming years. Moreover, small-cap biotech stocks like CORT can be volatile, and any paucity of analyst coverage (as the company itself warns (www.sec.gov)) or negative surprises can magnify stock swings. Investors should be prepared for earnings volatility and possible dilutive capital raises if the pipeline hits further delays (though Corcept’s cash cushion makes an equity raise less likely in the near term).

In sum, Corcept’s risk profile has intensified after the FDA’s response. The company’s fortunes rest on navigating these challenges: re-establishing a path to approval for relacorilant, sustaining Korlym’s cash flows against competition (amid scrutiny of its sales tactics), and advancing its pipeline without overextending financially. The above red flags warrant close investor attention.

Open Questions and Outlook

Looking ahead, several critical questions remain open for Corcept’s investment thesis:

– What will it take to win FDA approval for relacorilant? The FDA’s CRL cited the need for “additional evidence of effectiveness” despite positive Phase 3 results (www.biospace.com). Will Corcept need to run another costly trial for relacorilant in Cushing’s, or can it satisfy the FDA with existing or real-world data? The timeline for relacorilant’s potential approval is now pushed out indefinitely. Management, “surprised and disappointed” (www.biospace.com), will meet with regulators to determine the best path forward. Investors are waiting to learn if relacorilant’s issues are fixable in the near term or if this asset might be shelved. The outcome of these FDA discussions – and Corcept’s willingness to invest further in relacorilant – will determine if the drug can still become a future growth driver or if it’s effectively derailed.

– How resilient are Korlym’s sales and growth prospects? With relacorilant delayed, Korlym remains the workhorse sustaining Corcept. Thus far Korlym’s sales have grown steadily (20% in 2023 (www.biospace.com)) as more patients get diagnosed and treated. But will that momentum continue? The DOJ inquiry and scrutiny on marketing practices could force Corcept to dial back aggressive promotion (thecapitolforum.com), potentially slowing new patient adds. Competition from novel Cushing’s drugs is also increasing. Corcept argues that Cushing’s is underdiagnosed and that efforts to raise awareness are expanding the market (www.biospace.com). Yet an open question is how much runway is left for Korlym growth if it must compete on a more level playing field. Additionally, could generic Korlym arrive earlier than 2034 if other patent litigation doesn’t go Corcept’s way? For the next few years Korlym will be Corcept’s lifeblood – investors should watch prescription trends, competitor uptake, and any legal settlements or rulings that affect Korlym’s exclusivity.

– Will the ovarian cancer indication rescue relacorilant’s story? Corcept isn’t abandoning relacorilant – it also has tested the drug in oncology. The company filed an NDA in July 2025 for relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, and the FDA has accepted it with a PDUFA target date of July 11, 2026 (www.biospace.com). Notably, the Phase 3 ROSELLA trial met its primary endpoint, improving progression-free survival in ovarian cancer (www.nasdaq.com). This suggests relacorilant could have a meaningful benefit in that population. Will the FDA view this indication more favorably? The ovarian cancer application is separate from the Cushing’s use – different indication, data, and risk/benefit considerations. If approved in 2026, relacorilant could finally start generating revenue (in oncology) and validate Corcept’s cortisol modulation approach. However, commercializing a cancer drug is a new challenge for Corcept, and the market opportunity in platinum-resistant ovarian cancer, while significant, is competitive and complex. Investors are keenly awaiting the FDA’s decision in mid-2026. A win there could partly offset the Cushing’s setback and open a new therapeutic market for the company.

– How will Corcept leverage its strong cash position? With over half a billion dollars in cash on hand (www.nasdaq.com) and no debt, Corcept has strategic options. Will management use this war chest to fund aggressive R&D (e.g. a new trial for relacorilant or advancing other candidates like dazucorilant for ALS and miricorilant for NASH (www.nasdaq.com))? Or might Corcept pursue in-licensing or acquisitions to diversify its product base given the reliance on Korlym? So far, Corcept has grown organically, but the current turmoil could make it consider buying a revenue-generating asset to reduce risk. Another possibility is additional share buybacks if management sees the stock as significantly undervalued post-plunge – though investing in the pipeline likely takes priority. The way Corcept allocates capital in the next 1-2 years (internal development vs. external opportunities vs. shareholder returns) will signal management’s confidence in its pipeline and could influence the company’s growth trajectory. This is an open question that investors will be evaluating through any strategic updates or investor day commentary.

– Can management rebuild credibility with investors? The severity of the share price reaction suggests a loss of investor trust in management’s assurances. Hagens Berman (a shareholder rights law firm) is even investigating whether Corcept overstated relacorilant’s efficacy and prospects to investors (www.prnewswire.com). Going forward, management will need to provide frank guidance on the regulatory path and realistic expectations. Any missteps in communication or additional negative surprises could further impair confidence. Conversely, delivering on promises – for example, securing FDA approval in ovarian cancer, hitting financial targets, or resolving legal issues favorably – could help restore management’s credibility. This soft factor of investor confidence is especially important for a one-product biotech; open questions remain on how management will navigate the company through adversity and whether they can regain the market’s benefit of the doubt.

In conclusion, Corcept Therapeutics now finds itself at a crossroads. The 50% stock collapse on the FDA’s relacorilant CRL is a stark reminder of the risks inherent in biotech development. Yet the company is not without strengths – a profitable orphan drug business in Korlym, a solid balance sheet, and other shots on goal in its pipeline. Investors should stay alert to upcoming milestones: any FDA guidance on relacorilant for Cushing’s, the mid-2026 ovarian cancer decision, and developments in the DOJ/Teva legal matters. The path forward contains hurdles, but also opportunities if Corcept can course-correct. With so many moving pieces, CORT remains a high-risk, high-reward story, and current and prospective investors must weigh the company’s strong finances and past successes against the clear challenges and uncertainties that have emerged. The next few quarters – and management’s responses – will be critical in determining whether Corcept can stabilize and rebuild value after this dramatic setback.

Sources:** The information and analysis above are based on Corcept’s SEC filings, investor communications, and reputable financial media. Key sources include Corcept’s 10-K annual report (www.sec.gov) (www.sec.gov), press releases on financial results (www.biospace.com) and the FDA letter (www.biospace.com), as well as third-party analyses from Nasdaq/RTTNews (www.nasdaq.com), Zacks Equity Research (www.nasdaq.com) (www.nasdaq.com), GuruFocus (www.gurufocus.com), and investigative reports (Reuters, Capitol Forum) regarding legal issues (pm360online.com) (thecapitolforum.com). These sources are cited inline throughout the report to ensure accuracy and provide context for all factual claims and figures.

For informational purposes only; not investment advice.